Recent studies have suggested that the high tumor mutation burden and CD28 expression in exhausted CD8 T cells predict the response to immune checkpoint inhibitors (Hui et al., 2017; Yarchoan et al., 2017). This evidence concerns the gene CD8A and neoplasm.